[PDF][PDF] Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma
SY Ng, MS Davids - Clin Adv Hematol Oncol, 2014 - hematologyandoncology.net
SY Ng, MS Davids
Clin Adv Hematol Oncol, 2014•hematologyandoncology.netSelective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Page 1 224 Clinical Advances in Hematology & Oncology Volume 12, Issue 4 April 2014
Selective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Samuel Y. Ng, MD, PhD, and Matthew S. Davids, MD Abstract: ABT-199, a second-generation
BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell
lymphoma/leukemia 2 (Bcl-2). Bcl-2 is a key protein that inhibits the intrinsic mitochondrial …
Page 1 224 Clinical Advances in Hematology & Oncology Volume 12, Issue 4 April 2014
Selective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Samuel Y. Ng, MD, PhD, and Matthew S. Davids, MD Abstract: ABT-199, a second-generation
BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell
lymphoma/leukemia 2 (Bcl-2). Bcl-2 is a key protein that inhibits the intrinsic mitochondrial …
Abstract
ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). Bcl-2 is a key protein that inhibits the intrinsic mitochondrial pathway of apoptosis. First-generation
hematologyandoncology.net
